Filing Details
- Accession Number:
- 0001209191-19-014162
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-02-27 17:30:15
- Reporting Period:
- 2019-02-25
- Accepted Time:
- 2019-02-27 17:30:15
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1178879 | Amicus Therapeutics Inc. | FOLD | Pharmaceutical Preparations (2834) | 200422823 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1601896 | Jay Barth | C/O Amicus Therapeutics, Inc. 1 Cedar Brook Drive Cranbury NJ 08512 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-02-25 | 26,270 | $2.29 | 156,037 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-02-25 | 26,270 | $12.52 | 129,767 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2019-02-25 | 43,730 | $2.94 | 173,497 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-02-25 | 43,730 | $12.52 | 129,767 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (right to buy) | Disposition | 2019-02-25 | 26,270 | $0.00 | 26,270 | $2.29 |
| Common Stock | Stock Options (right to buy) | Disposition | 2019-02-25 | 43,730 | $0.00 | 43,730 | $2.94 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 68,730 | 2024-03-03 | No | 4 | M | Direct | |
| 6,270 | 2024-06-26 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 31 | Indirect | by Daughter |
Footnotes
- The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2018.
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.50 to $12.58. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- All of the options were fully vested and exercisable as of February 25, 2019.
Billionaire Hedge Funds
